Skip Navigation LinksHome > March 2014 - Volume 20 - Issue 3 > The Commensal Bacterium Faecalibacterium prausnitzii Is Prot...
Text sizing:
A
A
A
Inflammatory Bowel Diseases:
doi: 10.1097/01.MIB.0000440815.76627.64
Original Basic Science Articles

The Commensal Bacterium Faecalibacterium prausnitzii Is Protective in DNBS-induced Chronic Moderate and Severe Colitis Models

Martín, Rebeca PhD*,†,‡; Chain, Florian PhD*,†; Miquel, Sylvie PhD*,†; Lu, Jun; Gratadoux, Jean-Jacques*,†; Sokol, Harry MD, PhD*,†,§,‖; Verdu, Elena F. MD, PhD; Bercik, Premysl MD; Bermúdez-Humarán, Luis G. PhD*,†; Langella, Philippe PhD*,†,‡

Supplemental Author Material
Collapse Box

Abstract

Background:

The abundance of Faecalibacterium prausnitzii, an abundant and representative bacterium of Firmicutes phylum, has consistently been observed to be lower in patients with Crohn's disease than in healthy individuals. We have shown that both F. prausnitzii and its culture supernatant (SN) have anti-inflammatory and protective effects in a TNBS-induced acute colitis mouse model. Here, we tested the effects of both F. prausnitzii and its SN in moderate and severe DNBS-induced chronic colitis mouse models.

Methods:

Colitis was induced by intrarectal administration of DNBS. After either 4 or 10 days of recovery (severe and moderate protocols, respectively), groups of mice were intragastrically administered either with F. prausnitzii A2-165 or with its culture SN for 7 or 10 days. Three days before being sacrificed, colitis was reactivated by administration of a lower dose of DNBS. The severity of colitis at the time of being sacrificed was assessed by weight loss and macroscopic and microscopic scores. Myeloperoxidase (MPO) activity, cytokine levels, lymphocyte populations, and changes in microbiota were studied.

Results:

Intragastric administration of either F. prausnitzii or its SN led to a significant decrease in colitis severity in both severe and moderate chronic colitis models. The lower severity of colitis was associated with down-regulation of MPO, pro-inflammatory cytokines, and T-cell levels.

Conclusions:

We show, for the first time, protective effects of both F. prausnitzii and its SN during both the period of recovery from chronic colitis and colitis reactivation. These results provide further evidence that F. prausnitzii is an anti-inflammatory bacterium with therapeutic potential for patients with inflammatory bowel disease.

Copyright © 2014 Crohn's & Colitis Foundation of America, Inc.

You currently do not have access to this article.

You may need to:

Note: If your society membership provides for full-access to this article, you may need to login on your society’s web site first.

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.